Study Evaluating Bosutinib-Exemestane Combination Vs Exemestane Alone in Post Menopausal Women With Breast Cancer

NCT00793546 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

42

Enrollment

INDUSTRY

Sponsor class

Stopped See termination reason in detailed description.

Conditions

Advanced Breast Cancer

Interventions

DRUG: Bosutinib
DRUG: exemestane
DRUG: Exemestane

Sponsor

Pfizer